Back to User profile » Dr Yayi He

Papers published by Dr Yayi He:


Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma

Wang H, Chen S, Meng D, Wu C, Zhu J, Jiang M, Ning J, Wu S, Wu L, Li J, Chen B, Zhao S, Li W, Yu J, Fang Q, Zhu J, Zhao W, He Y, Zhou C

OncoTargets and Therapy 2021, 14:2953-2965

Published Date: 4 May 2021

Single-Cell Sequencing, an Advanced Technology in Lung Cancer Research

Wang H, Meng D, Guo H, Sun C, Chen P, Jiang M, Xu Y, Yu J, Fang Q, Zhu J, Zhao W, Wu S, Zhao S, Li W, Chen B, Wang L, He Y

OncoTargets and Therapy 2021, 14:1895-1909

Published Date: 16 March 2021

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer

Sun C, Zhang L, Zhang W, Liu Y, Chen B, Zhao S, Li W, Wang L, Ye L, Jia K, Wang H, Wu C, He Y, Zhou C

OncoTargets and Therapy 2020, 13:6475-6483

Published Date: 3 July 2020

Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review

Chen S, He Y, Liu J, Chen X, Yu J, Li W, Chen B, Sun C, Zhou C

OncoTargets and Therapy 2019, 12:11305-11311

Published Date: 19 December 2019

Comparison of Double Sleeve Lobectomy by Uniportal Video-Assisted Thoracic Surgery (VATS) and Thoracotomy for NSCLC Treatment

Wu L, Wang H, Cai H, Fan J, Jiang G, He Y, Jiang L

Cancer Management and Research 2019, 11:10167-10174

Published Date: 2 December 2019

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC

Yi C, He Y, Xia H, Zhang H, Zhang P

OncoTargets and Therapy 2019, 12:7329-7336

Published Date: 6 September 2019

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer

Deng J, Zhao S, Zhang X, Jia K, Wang H, Zhou C, He Y

OncoTargets and Therapy 2019, 12:7347-7353

Published Date: 6 September 2019

Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment

Wang H, Zhao S, Zhang X, Jia K, Deng J, Zhou C, He Y

OncoTargets and Therapy 2019, 12:7281-7288

Published Date: 5 September 2019

TIM-3, a promising target for cancer immunotherapy

He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch FR

OncoTargets and Therapy 2018, 11:7005-7009

Published Date: 16 October 2018

sLAG-3 in non-small-cell lung cancer patients’ serum

He Y, Wang Y, Zhao S, Zhao C, Zhou C, Hirsch FR

OncoTargets and Therapy 2018, 11:4781-4784

Published Date: 13 August 2018

Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules

He Y, Yang Y, Kuang P, Ren S, Rozeboom L, Rivard CJ, Li X, Zhou C, Hirsch FR

OncoTargets and Therapy 2017, 10:5915-5926

Published Date: 13 December 2017

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases

He YY, Sun WW, Wang Y, Ren SX, Li XF, Li JY, Rivard CJ, Zhou CC, Hirsch FR

OncoTargets and Therapy 2016, 9:2409-2414

Published Date: 21 April 2016